Showing 3751-3760 of 4164 results for "".
- Enrollment Begins for Ocular Therapeutix’s Axpaxli Phase 3 SOL-R Wet AMD Studyhttps://modernod.com/news/ocular-therapeutixs-axpaxli-phase-3-sol-r-wet-amd-study-begins-enrollment/2482382/Ocular Therapeutix announced that the first patients have been enrolled in the phase 3 SOL-R clinical trial evaluating repeat dosing of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of patients with wet age-related macular degeneration (wet AMD). Accor
- 4DMT Announces Phase 2 PRISM Interim Results for Intravitreal 4D-150 in Wet AMDhttps://modernod.com/news/4dmt-announces-phase-2-prism-interim-results-for-intravitreal-4d-150-in-wet-amd/2482364/4D Molecular Therapeutics announced initial interim 24-week landmark data from the population extension cohort of the PRISM phase 2 clinical trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population. The data were presented by Raj K. Maturi, MD, at the A
- Heidelberg Engineering Introduces Faster OCT Angiography with Spectralis Shift Technologyhttps://modernod.com/news/heidelberg-engineering-introduces-faster-oct-angiography-with-spectralis-shift-technology/2482359/Heidelberg Engineering has received FDA clearance of the Spectralis OCTA Module with Shift technology, which is designed to reduce acquisition time by 50%.[1] The preset OCTA speed of 125 kHz helps streamline workflow, enhance clinical e
- Okyo Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101https://modernod.com/news/okyo-pharma-to-initiate-neuropathic-corneal-pain-trial-for-ok-101/2482353/Okyo Pharma announced its plan to advance OK-101 into a phase 2 clinical trial of neuropathic corneal pain which is expected to begin in Q3 2024. This 1-year study is supported by preclinical animal model data and statistically significant pain relief observe
- Hospital in Poland is First Teaching Institution to Use Haag-Streit's Eyesi Indirect Ophthalmoscope ROP Simulatorshttps://modernod.com/news/hospital-in-poland-is-first-teaching-institution-to-use-haag-streits-eyesi-indirect-ophthalmoscope-rop-simulators/2482352/Haag-Streit announced it has enabled trainee ophthalmologists across Poland to become competent in the skills required for effective ROP examination in a lifelike, yet risk-free, environment. The University Clinical Hospital, Poland, will be the first teaching institution globally to use four Eye
- NurExone’s Exosome-Based Exopten Therapy Studied to Treat Glaucomahttps://modernod.com/news/nurexones-exosome-based-exopten-therapy-studied-to-treat-glaucoma/2482339/NurExone Biologic announced a preclinical study to explore the potential of one of the company’s exosome-based therapies, Exopten, in regenerating damaged optic nerves. The study is NurExone Biologic’s latest step in expanding potential clinical indications for its exosome-loaded
- 4DMT Receives FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of GAhttps://modernod.com/news/4dmt-receives-fda-clearance-of-ind-application-for-4d-175-genetic-medicine-for-the-treatment-of-ga/2482330/4D Molecular Therapeutics announced FDA clearance of its investigational new drug application (IND) for 4D-175, an R100 vector-based intravitreal genetic medicine for the treatment of patients with geographic atrophy (GA). The phase 1 GAZE clinical trial will assess 4D-175 in
- J&J's Nipocalimab Significantly Improves Sjögren’s Disease Activity in a Phase 2 Studyhttps://modernod.com/news/jjs-nipocalimab-significantly-improves-sjogrens-disease-activity-in-a-phase-2-study/2482323/Johnson & Johnson announced that patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the phase 2 DAHLIAS dose-rang
- Beacon Therapeutics Treats First Patient in VISTA Trial of AGTC-501 for XLRPhttps://modernod.com/news/beacon-therapeutics-treats-first-patient-in-vista-registrational-trial-for-agtc-501/2482319/Beacon Therapeutics announced the treatment of the first patient in its registrational VISTA clinical trial with its lead asset, AGTC-501 (laruparetigene zovaparvovec). VISTA is a global randomized, controlled, masked, multicenter pivotal study evaluating the efficacy, safety, and
- Galimedix Establishes SAB in Advance of Phase 2 Study of GAL-101 for Dry AMDhttps://modernod.com/news/galimedix-therapeutics-establishes-scientific-advisory-board-in-advance-of-phase-2-study-of-gal-101-for-dry-amd/2482313/Galimedix Therapeutics has formed a Scientific Advisory Board (SAB) to provide advice and direction to the company for the development of its compound GAL-101 for the treatment of dry age-related macular degeneration (AMD). The SAB consists of retina experts from both clinical prac